Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180644 | 0.85 | CES2 (0.32) | CES2CES1CA1CA2CA4 | |
| SCHEMBL24901032 | 0.84 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL10179743 | 0.83 | CES2 (0.42) | CES2CES1CA1CA2CA4 | |
| SCHEMBL29671299 | 0.83 | ELANE (0.44) | — | |
| SCHEMBL10180776 | 0.81 | CES2 (0.41) | CES2CES1EPHX2 | |
| SCHEMBL10181509 | 0.80 | EPHX2 (0.35) | CES2CES1CA1CA2CA4 | |
| SCHEMBL474387 | 0.79 | CES2 (0.39) | CES2CES1CA1CA2CA4 | |
| SCHEMBL20156673 | 0.78 | CES2 (0.38) | CES2CES1CA1CA2CA4 | |
| SCHEMBL10181736 | 0.76 | CES2 (0.41) | CES2CES1CA1CA2CA4 | |
| SCHEMBL31006941 | 0.76 | CYP4F2 (0.47) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544518-B2 | Rapid quantitative analysis of proteins or protein function in complex mixtures | UNIVERSITY OF WASHINGTON (US) | 2009-06-09 | — | — | US | claimed |
| US-20050233399-A1 | Rapid quantitative analysis of proteins or protein function in complex mixtures | UNIVERSITY OF WASHINGTON | 2005-10-20 | — | — | US | claimed |
| JP-3256539-B2 | — | — | 2002-02-12 | — | — | JP | claimed |
| EP-0547142-A4 | — | MICROPROBE CORP (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0547142-A1 | SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE | EPOCH PHARMACEUTICALS, INC. (US) | 1993-06-23 | — | — | EP | claimed |
| WO-1992003464-A1 | SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE | MICROPROBE CORPORATION (US) | 1992-03-05 | — | — | WO | claimed |
| CN-116964076-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-10-27 | — | — | CN | disclosed |
| CN-116829573-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022191283-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED USING SAME | 味の素株式会社 | 2022-09-15 | — | — | WO | disclosed |
| US-10660970-B2 | Nucleic acid constructs and methods of using the same | GENEVANT SCIENCES GMBH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20130244122-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | ONUKI MASAMICHI (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120219866-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2475041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME | Mitsubishi Chemical Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027325-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| US-5574142-A | DRUG DELIVERY TO TARGET CELLS, ANTISENSE OLIGODEOXYNUCLEOTIDES | MICROPROBE CORPORATION (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1994013325-A9 | PEPTIDE LINKERS FOR IMPROVED OLIGONUCLEOTIDE DELIVERY | — | 1994-08-18 | — | — | WO | disclosed |
| WO-1994013325-A2 | PEPTIDE LINKERS FOR IMPROVED OLIGONUCLEOTIDE DELIVERY | MICROPROBE CORPORATION (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660970-B2 | Nucleic acid constructs and methods of using the same | EXOSC5, DIS3, MTREX | CES2 1937/4885CES1 2573/4885CA1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.